TH71127B - Antibody molecules that are specific to human IL-6. - Google Patents

Abstract

DC60 (02/03/50) This invention involves a dither-specific antibody molecule. IL-6 Antigenic Minant, Therapeutic Use of Antibody Molecules and how for produce molecules of such antibodies The invention involves antibody molecules that are specific to dieters. IL-6 Antigenic Minant, Therapeutic Use of Antibody Molecules and how for Produce such antibody molecules, patent drug

Claims (4)

Disclaimer (all) which will not appear on the advertisement page: Edit 29/03/2019 Page 1 of 2 pages Disclaimer 1. For CDR-L3 ------------ -------------------------------------------------- ------------ ------ 20/12/2018 ------ (OCR) Page 1 of 2 pages Disclaimer 1. For CDR-L3 2. Antibody According to claim 1, the weight includes the gH13 sequence (SEQ IDN0: 11) 3. Antibodies according to claim 1, where the light chain is composed of the gLIO sequence (SEQ ID N0: 13) 4. Antibodies A isolated neutralized that is specific to human IL-6, consisting of a heavy chain composed of the gH13 sequence (SEQ ID N0: 11) and a light chain containing the gLIO sequence (SEQ ID N0: 13). 1. 6. Isolated DNA sequence that encodes the heavy and / or light chains of the antibody according to any Clause 1 to 5. Clause 1 or SEQ IDNO.-15 or Nucleotide 58. -2008 SEQ ID N0: 15 1. 9. Carrier of cloning or expression composed of one or more DNA sequences in any clause. Clause Clause 6-8 1 0. Claim 9, where the carrier is assembled in a predetermined sequence In SEQ IDN0: 15 and sequences defined in SEQ IDNO: 17 1 1. Process for producing antibodies with human IL-6 binding specificity comprising host cell culture. And antibody isolation page 2 of the number 2. Page 1 2. The pharmaceutical component containing the antibody according to any of the claims 1 to 5 in combination with an adjuvant, diluent, or accepted carrier. Yes, in one or more pharmaceuticals. ------------ 1. Isolated neutralized antibodies that are specific to human IL-6 constituted by human IL-6. Include a heavy chain, where the changeable domain of the heavy chain consists of a sequence defined in SEQ ID NO: 5 for CDR-H1, a sequence defined in SEQ ID NO: 6 for CDR-H2 and a sequence. That is defined in the SEQ ID NO: 7 for the CDR-H3 and is further included with the lighter chain, where Light chain changeable domains include a sequence defined in the SEQ ID NO: 8 for CDR-L1, a sequence defined in the SEQ ID NO: 9 for a CDR-L2, and a sequence defined in the SEQ ID. NO: 10 for CDR-L3 2. Antibody neutralized as defined in claim 1 where the changeable domain of the chain is heavy. It consists of a sequence defined in SEQ ID NO: 5 for CDR-H1, a sequence defined in SEQ ID NO: 6 for CDR-H2, and a defined sequence for SEQ ID NO: 7 for CDR-H3. Neutral that is specific to the IL-6 of people composed of light chain, the light chain changeable domain consists At least one CDR of a CDR with a sequence defined in SEQ ID NO; 8 for CDR-L1, CDR with a sequence defined in SEQ ID NO: 9 for a CDR-L2, and a CDR with a sequence defined in SEQ. ID NO: 10 for CDR-L3 4. The neutralizing antibody as defined in claim 1 or claim 2 with additional components containing light chains. The light chain changeable domain contains at least one CDR of the CDR with a sequence defined in the SEQ ID NO: 8 for CDR-L1, a CDR with a sequence defined in SEQ ID NO: 9 for CDR-L2. And CDRs with a sequence defined in SEQ ID NO: 10 for CDR-L3 1. For CDR-L1, sequence defined in SEQ ID NO: 9 for CDR-L2 and sequence defined in SEQ ID NO: 10. For CDR-L3 6. Antibody, as defined in any of Claims 1 through 5, which is heavy chain, contains the gH sequence 13 (SEQ ID NO: 11). 7. Antibody as defined in Clause 1. Holds one of the rights 1 to 5, which is light chain, containing gL 10 (SEQ ID NO: 13) sequence. 8. Neutralized antibodies specific to IL-6 of heavy chain people. Containing the gH13 sequence (SEQ ID NO: 11) and the light chain containing the gL 10 sequence (SEQ ID NO: 13) 9. Neutralized antibodies specific to the IL-6 of people with the changeable domain of the light chain. include The sequences that are at least 60 percent similar or similar to the Changeable domain of the 8th claim antibody and that hit the heavy chain's changeable main are: A sequence containing at least 60 percent similarity or similarity to the changeable domain of the heavy chain of antibodies of the 8th claim 1 0 neutralized antibody specific to IL-6 of heavy chain people. Containing the sequence defined in the SEQ ID NO: 2 and the lighter chain containing Sequence defined in SEQ ID NO: 4 1 1. A neutralizing antibody specific to IL-6 of heavy chain people. Containing The sequence is defined in the SEQ ID NO: 16 and the light chain containing Sequence defined in SEQ ID NO: 18 1 2. A neutralized antibody specific to IL-6 of heavy chain people. And the lighter chain has at least 60 percent similarity or similarity to the corresponding heavy chain and the corresponding light chain of the antibody of claim 11 1. 3. neutralizing antibodies that fully belong to the person or that of the person who have The affinity of human IL-6 adherence is 500 pM or better. 1 4. A neutralizing antibody that makes it a person, of a fully human or chimeric type with an affinity of Human IL-6 adherence equal to 50 pM or better 1 5. Epitope on IL-6 of persons bound by antibody of Claim 8 1 6. Epitope as required. In claim 15, consisting of amino acid units S47, C50, E93, R104, F105, E106, T149, K150, A153, Q156, Q159 and S169 of human IL-6. 7. Epitope. Set out in claim 16, containing the amino acid units S47, C50, E93, R104, F105, E106, T149, K150, A153, Q156, Q159 and S169 and one or more selectable units of C44, S53, A58, V96, Q152, Q154, N155, W157, T163, L165, and E172 1 8. Neutralized antibodies that are fully human, fully human, or IL-6 specific chimeric type. Of people attached to the epitope of claim 15, claim 16 or claim 17 1 9. neutralizing antibodies that make them fully belonging to a person, of a person or a chimeric type. With Specificity to human IL-6 with cross block, the antibody binding of Claim 8 against human IL-or cross-blocked from human IL-6 binding by antibody of claim 8 2 0 neutralized antibody specific to IL-6 of The inhibitory activity of 0.038 nM of 0.038 nM subjects was 50% inhibited at low concentrations of 100 pM. Such inhibitory activity was measured primarily using the multiplication of IL-6-induced T1165 cells. 2 1. A neutralized antibody specific to human IL-6 that can Inhibition of IL-6 activity of 3.84 nM people was 50 percent at concentrations below 1 nM.Such inhibitory activity was measured using MCP-1 production by IL-6 and SIL-6R responsive HUVECs. Principle 2 2. Antibody neutral as defined in claim 20 or claim 21, where crossblocks the antibody binding of claim 8 to the IL-6 of Person 2 3. Antibody, as defined in any of Claim 19-22, which has a human IL-6 binding affinity of 50 pM or better. Isolated, given the heavy chain code. And / or the lighter chain of Antibodies, as defined in any of Claims 1 through 14 or 18 to 23 2. 5. Isolated DNA sequence as defined in claim 24, where the chain-coded DNA sequence. Heavy Sequence defined in SEQ ID NO: 12 or SEQ ID NO: 15 or SEQ ID 58-2008 nucleotide NO: 15 2 6. Isolated DNA sequence as defined in claim 24. Where the DNA sequence that defines the light chain code consists of Sequence defined in SEQ ID NO: 14 or SEQ ID NO: 17 or SEQ ID 61-705 nucleotide NO: 17 2. 7. Cloning carriers or expressions containing one or more DNA sequences. As set out in any of Claims 24-26 2 8. Carrier, as set out in claim 27, where the carrier consists of sequence Defined in the SEQ ID NO: 15 and the sequence defined in the SEQ ID NO: 17 2 9. Host cells that contain Vectors of cloning Or of expression One or more carriers as defined in claim 27 or claim 28 3 0. Process for producing antibodies with IL-6 binding specificity of people consisting of host cell culture. Rights 29 and Antibody Isolation 3 1. Pharmaceutical mixtures containing Antibodies as defined in Any of the claims 1 to 14 or 18 to 23, in conjunction with one or more pharmaceutical additives, diluents or carriers 3. 2. Pharmaceutical Mixture as defined in Claim 31 with Supplemental Containing 3 other active ingredients 3. Antibody as set forth in any Clause 1 through Claim 1 through 14 or 18 to 23 or a Pharmaceutical Mixture as defined in Claim 31 or Claim 32 for Use. In the treatment or prevention of disease disorders with IL-6-mediated or co-mediated IL-6 levels of increased 3. 4.Use of neutralizing antibodies that fully neutralize a person or that of a person. The human IL-6 binding relationship was 500 pM or better in drug production. For treating or preventing disorders with IL-6-mediated or co-mediated IL-6 levels.